Abivax SA Sponsored ADR is surging as investors respond to intense takeover speculation involving big pharma names such as AstraZeneca and Eli Lilly, following reports that an exclusive data-review period ended on March 23. The company has officially denied any deal talks, but the rumors are still fueling heavy trading and strong buying interest.
Adding to the momentum, Jefferies has initiated coverage with a Buy rating and a $160 price target, signaling strong confidence in Abivax’s prospects. The bank highlighted the market potential and relatively de-risked path of the company’s ulcerative colitis drug candidate, obefazimod, reinforcing the bullish case for the stock.
Together, the M&A chatter and the upbeat analyst call have turned Abivax into one of the session’s most actively watched movers. Traders are now speculating on both the possibility of a future acquisition and the long-term value of its lead therapy, making the stock a focal point for risk-tolerant investors.
https://www.tipranks.com/news/catalyst/why-abivax-sa-sponsored-adr-is-suddenly-sinking
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.